Peanut Drug Short Sellers Must Beware of Aimmune Sales Potential

(Bloomberg) -- Investors looking to bet against a strong start to sales of Aimmune Therapeutics Inc.’s peanut allergy medicine should proceed with caution, according to Piper Jaffray.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.